Bostan E, Zaid F, Karaduman A, et al. - When patients were divided into omalizumab ± oral antihistamines and only oral antihistamines treatment groups, no statistically significant association was observed between COVID-19 RT-PCR positivity and the type of treatment administered for chronic urticaria. Omalizumab appears to be safe in the COVID-19 era.

• The authors carried out a descriptive cross-sectional study of 233 patients diagnosed with chronic spontaneous urticaria in a tertiary referral hospital.

• There were 160 female patients and 73 male patients.

• The mean age of participants was 44.76.

• One hundred twenty-five of the 233 patients with chronic urticaria had symptoms associated with COVID-19 infection.

• COVID-19 RT-PCR testing was performed on 156 patients.

• The COVID-19 RT-PCR test resulted in 15 positive cases out of 156 patients.